Ipsen - Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026

Ipsen announced the completion of its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK asset. This acquisition adds a first-in-class asset to Ipsen's Rare Disease pipeline. The announcement also includes a corrective statement regarding voting rights disclosure as of June 30, 2026.